|
|
Volumn 2012, Issue , 2012, Pages 410-416
|
|
Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CISPLATIN;
CYTARABINE;
DEXAMETHASONE;
ETOPOSIDE;
IDARUBICIN;
MONOCLONAL ANTIBODY;
RITUXIMAB;
ALLOTRANSPLANTATION;
BIOPSY;
DISEASE FREE SURVIVAL;
DRUG THERAPY;
GENE EXPRESSION PROFILING;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
LARGE CELL LYMPHOMA;
METHODOLOGY;
ONCOLOGY;
PROGNOSIS;
RECURRENT DISEASE;
REVIEW;
SALVAGE THERAPY;
STEM CELL TRANSPLANTATION;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BIOPSY;
CISPLATIN;
CYTARABINE;
DEXAMETHASONE;
DISEASE-FREE SURVIVAL;
DRUG THERAPY;
ETOPOSIDE;
GENE EXPRESSION PROFILING;
HUMANS;
IDARUBICIN;
LYMPHOMA, LARGE B-CELL, DIFFUSE;
MEDICAL ONCOLOGY;
PROGNOSIS;
RECURRENCE;
SALVAGE THERAPY;
STEM CELL TRANSPLANTATION;
TRANSPLANTATION CONDITIONING;
TRANSPLANTATION, HOMOLOGOUS;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 84878872002
PISSN: None
EISSN: 15204383
Source Type: Journal
DOI: 10.1182/asheducation.v2012.1.410.3798518 Document Type: Review |
|
Times cited : (27)
|
|
References (0)
|
